Anoro Ellipta

Anoro Ellipta® is a prescription inhaler used for the long-term maintenance treatment of COPD (chronic obstructive pulmonary disease). It combines two bronchodilators - a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) - to help keep airways open over time. It is not approved for asthma and should not be used for sudden breathing symptoms.

• Contains umeclidinium (LAMA) and vilanterol (LABA)
• Used once daily for ongoing COPD management
• Helps relax airway muscles for easier breathing over time
• Not for asthma treatment or asthma-related symptoms
• Not a rescue inhaler for sudden shortness of breath

A healthcare provider will determine if this medication is appropriate based on your condition.

Anoro Ellipta® is a dry powder inhaler (DPI) that you inhale through your mouth, typically once daily at the same time each day. It’s designed for regular use to help maintain breathing stability - not for immediate relief.

• Inhaled through the Ellipta device (breath-activated)
• Taken once daily as prescribed
• Do not use more than one dose per day
• Avoid combining with other LABA or similar inhalers unless directed
• Use a rescue inhaler for sudden breathing problems

Using it consistently helps maintain its effect. If symptoms suddenly worsen, seek medical attention rather than increasing your dose.

Anoro Ellipta® can cause side effects, although not everyone experiences them. Some are related to the respiratory system, while others may affect different parts of the body.

• Common: sore throat, sinus symptoms, cough, constipation
• Possible: muscle spasms, chest discomfort, diarrhea
• May affect heart rate or blood pressure in some people
• Get medical help right away if breathing worsens after use
• Contact your provider if you notice chest pain, eye pain, or difficulty urinating

If symptoms feel unusual or persistent, discuss them with your provider. Refer to the Important Safety / Prescribing Information for full details.

Anoro Ellipta® is a prescription medication, so a provider must review your condition before prescribing it. It is typically considered for COPD, not asthma.

• Complete an online consultation
• A provider reviews your health history
• Prescription is issued if appropriate
• Medication is sent to a pharmacy or delivered

Not everyone will qualify, and treatment decisions are based on medical safety.

No - Anoro Ellipta® is not approved for asthma treatment. It is designed for COPD and may not be appropriate for asthma management.

• Does not contain an inhaled corticosteroid (ICS)
• LABA use without ICS is not recommended for asthma
• Using it for asthma may increase safety risks

If you have asthma, your provider will prescribe a medication specifically designed for asthma control.

No - Anoro Ellipta® is not a rescue inhaler and should not be used during a sudden breathing episode.

• It does not act quickly enough
• Use a rescue inhaler for immediate relief
• Delaying proper treatment may worsen symptoms

If your breathing does not improve after using a rescue inhaler, seek medical help right away.

Yes - if you have sudden breathing symptoms, you will still need a rescue inhaler. Anoro Ellipta® is for long-term control, not quick relief.

• Used daily for maintenance
• Rescue inhalers treat sudden symptoms
• Both may be part of your treatment plan

If you need your rescue inhaler more often, contact your provider.

If you miss a dose, take it as soon as you remember. If it’s close to your next scheduled dose, skip the missed one.

• Do not take two doses in one day
• Stick to your regular schedule
• Use reminders if needed

Consistent use helps maintain effectiveness.

No - you should not take extra doses unless directed by your provider. Taking more than prescribed may increase side effects.

• Does not provide immediate relief
• Overuse may increase risks
• Use your rescue inhaler instead
• Follow always the instructions of your provider

It depends on the type of inhaler. Some combinations may be appropriate, but others can increase risks.

• Avoid using multiple LABA inhalers together
• Avoid combining with similar anticholinergic medications
• Always check with your provider

Your provider will help you choose safe combinations.

Yes - you can eat or drink normally after using Anoro Ellipta®.

• No specific food restrictions are listed
• Maintain a balanced diet
• Stay hydrated

There are no specific restrictions listed, but it’s best to be cautious.

• Moderate alcohol intake is generally acceptable
• Avoid excessive drinking
• Monitor how you feel

Most people can continue normal activities like driving, but it depends on how your body responds.

• Watch for dizziness or palpitations
• Avoid driving if you feel unwell
• Allow time to adjust to the medication

Use caution if you have glaucoma or urinary retention issues, as this medication may worsen these conditions.

• Inform your provider before starting
• Monitor for eye pain or vision changes
• Watch for difficulty urinating

If symptoms occur, contact your provider promptly.

Yes - Anoro Ellipta® is a prescription medication. A healthcare provider must evaluate your condition before prescribing it.

• Requires medical review
• Typically prescribed for COPD
• Not intended for asthma treatment

US Quick Health can simplify the process, but provider approval is required.

Replace your inhaler based on the dose counter or expiration date, whichever comes first.

• Do not use once the counter reaches zero
• Follow expiration instructions
• Old inhalers may not deliver correct doses

Anoro Ellipta® (Umeclidinium/Vilanterol 62.5/25 mcg) - combination inhaler (LAMA + LABA) dry powder inhaler (DPI) used for maintenance treatment of COPD; not for acute bronchospasm. / Source: NCBI

Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dbd0671-c565-40c5-bf0f-e324db26799c / Published: Not clearly shown on DailyMed